Abstract:Objectives B cells are important in the pathogenesis of multiple sclerosis. It is yet unknown which subsets may be involved, but atypical B cells have been proposed as mediators of autoimmunity. In this study, we investigated differences in B‐cell subsets between controls and patients with untreated and anti‐CD20‐treated multiple sclerosis. Methods We recruited 155 participants for an exploratory cohort comprising peripheral blood and cerebrospinal fluid, and a validation cohort comprising peripheral blood. Flow cytometry was used to characterize B‐cell phenotypes and effector functions of CD11c+ atypical B cells. Results There were no differences in circulating B cells between controls and untreated multiple sclerosis. As expected, anti‐CD20‐treated patients had a markedly lower B‐cell count. Of B cells remaining after treatment, we observed higher proportions of CD11c+ B cells and plasmablasts. CD11c+ B cells were expanded in cerebrospinal fluid compared to peripheral blood in controls and untreated multiple sclerosis. Surprisingly, the proportion of CD11c+ cerebrospinal fluid B cells was higher in controls and after anti‐CD20 therapy than in untreated multiple sclerosis. Apart from the presence of plasmablasts, the cerebrospinal fluid B‐cell composition after anti‐CD20 therapy resembled that of controls. CD11c+ B cells demonstrated a high potential for both proinflammatory and regulatory cytokine production. Interpretation The study demonstrates that CD11c+ B cells and plasmablasts are less efficiently depleted by anti‐CD20 therapy, and that CD11c+ B cells comprise a phenotypically and functionally distinct, albeit heterogenous, B‐cell subset with the capacity of exerting both proinflammatory and regulatory functions.

B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis

B-cell depletion therapy for multiple sclerosis

B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies

Anti‐B cell therapies in multiple sclerosis

Systems Analysis of Immune Changes after B-cell Depletion in Autoimmune Multiple Sclerosis

B cells reappear less mature and more activated after their anti-CD20–mediated depletion in multiple sclerosis

Targeting B cells in multiple sclerosis

CD11c+ B cells in relapsing–remitting multiple sclerosis and effects of anti‐CD20 therapy

B cell depletion therapies in autoimmune disease: advances and mechanistic insights

Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy

Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy

Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response

Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy

Functional impairment of CD19+CD24hiCD38hi B cells in neuromyelitis optica spectrum disorder is restored by B cell depletion therapy

Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease

IL-10-providing B cells govern pro-inflammatory activity of macrophages and microglia in CNS autoimmunity

B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans

A new perspective on therapies involving B-cell depletion in autoimmune diseases

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis

The Dual Effects of B Cell Depletion on Antigen-Specific T Cells in BDC2.5NOD Mice

Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis